Abstract library

329 results for "size".
#296 Tumor Size Correlates With Malignancy in Non-Functioning Pancreatic Endocrine Tumor
Introduction: Tumor size is a criterion of staging in non-functioning pancreatic endocrine tumors (NF-PET), as well as a predictor of outcome after curative resection.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Massimo Falconi
#1803 Type 3 Gastric Neuroendocrine Neoplasms: Relationship Between Tumor Size, Ki67 and Clinical Outcome
Introduction: Sporadic type 3 gNENs are usually malignant with high metastatic potential, mostly large, with a high grade histology. However, little is known on the relationship between tumor size, proliferative index Ki67, and clinical outcome
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr. Francesco Panzuto
#1479 Comparison of Radiological and Histological Tumor Size in Pancreatic Neuroendocrine Neoplasm
Introduction: Radiological tumor size of pancreatic neuroendocrine neoplasms (PNEN) is crucial for management especially for asymptomatic, small lesions.
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: Stefano Partelli
#2200 Tumor Size Correlates with Grading in Nonfunctioning Pancreatic Neuroendocrine Tumors and Is Not Age-Dependent
Introduction: Tumor growth and Ki67 value increase are associated with aggressiveness in nonfunctioning pancreatic neuroendocrine tumours (NF-PanNET), but their natural history is largely unknown. It is unknown if the evolution of NF-PanNET is time-dependant.
Conference: 15th Annual ENETS conference (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Francesca Muffatti
#2051 Do We Need Hormonal Therapy for Pancreatic Neuroendocrine Tumors? An Effort to Reduce the Size of PanNETs
Introduction: Pancreatic neuroendocrine tumors although rare , have been significantly increased over the past few decades. They range from indolent to highly aggressive in nature. Just like breast and endometrial carcinoma are hormonal dependant,
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zaidi S S A, ...
#1165 Discrepancy Between Radiologic and Pathologic Measurements in Pancreatic Neuroendocrine Tumors: A Retrospective Study on 199 Patients
Introduction: Preoperative radiologic size of pancreatic neuroendocrine tumors (PNET) is a crucial parameter in selection of appropriate treatment especially for incidentally discovered lesions (<20 mm). The current guideline bases the therapeutic recommendations on the pathologic size.
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: MD Anna Malpaga
Keywords: size NET
#2033 Ki-67 and Presence of Liver Metastases Predicts Progression in Pancreatic Neuroendocrine Neoplasms (pNENs)
Introduction: In pancreatic neuroendocrine neoplasms (pNENs), size ≤20 mm and Ki-67 ≤2% suggest indolent behavior, but no factor alone can predict prognosis.
Conference: 15th Annual ENETS conference (2018)
Category: Pathology - grading, staging
Presenting Author: MD, PhD Massimo Milione
#3045 Reliability and Agreement of Radiological and Pathological Tumor Size in Patients with MEN1-Related Pancreatic Neuroendocrine Tumors: Results from a Population-Based Cohort
Introduction: Pancreatic neuroendocrine tumors (pNETs) are the most lethal manifestation in patients with multiple endocrine neoplasia type 1 (MEN1). Tumor size is still regarded as the main prognostic factor and therefore used for surgical decision making.
Conference: 17th Annual ENETS Conference (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: MD, MSc Dirk-Jan van Beek
#1583 The Clinical Pathological Characteristics and Prognostic Factors of Rectal Neuroendocrine Tumors- A Retrospective Analysis Based on Multi Center Data
Introduction: The pathological characteristics and prognosis factors of rectum neuroendocrine tumor still have a lot of uncertainty.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Wei Gengzhou
Authors: Gengzhou W, Wei W, Xingyu F, ...
#3075 Telotristat Makes Significant Difference on Symptoms and Serotonin Levels in a Population with Widespread GI-NET and Severe Carcinoid Syndrome
Introduction: In spite of new treatments like PRRT or everolimus there is a clinical need for systemic therapies that complement SSAs (somatostatin analogs) and antidiarrheal agents in the treatment of carcinoid syndrome, a late stage problem in s-i-NET. Telotristat is a promising addition to our therapeutic arsenal.
Conference: 17th Annual ENETS Conference (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD PhD Kristina Linder Ekberg
Authors: Linder Ekberg K, ...
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss on any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team